Floatz logo

Epoetin Alfa

Neoplasm

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

928 Active assets in the Neoplasm cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Epoetin Alfa is also rated in:

anemiaDormant
BBB
Indicative ·
79 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
71 / 100
View asset →
precancerous conditionDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →